National registry for women with lymphangioleiomyomatosis
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial is a national health registry that collects medical information from women with lymphangioleiomyomatosis (LAM), a rare lung condition. It helps researchers better understand who has LAM and what their health looks like over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female
- You have a definite or probable LAM diagnosis, or your doctors recommend you be included
- Your lung scans show widespread (diffuse) cyst-like changes
- You can sign the informed consent form
- You can reliably be contacted and followed up for registry updates
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is a registry study that collects health information from adults diagnosed with Hodgkin or non-Hodgkin lymphoma. It may help researchers learn about lymphoma care and outcomes by understanding real-world patient experiences.
This study looks at the natural history and disease process of lymphangioleiomyomatosis (LAM), a rare lung disease that mostly affects women. It may help understand how LAM progresses and how it affects daily life, and may include exercise testing and other evaluations.
This trial examines tiny particles called extracellular vesicles from your blood to see if they can help doctors understand lung problems in women with lymphangioleiomyomatosis (LAM) or tuberous sclerosis complex (TSC). It may help find new ways to track the disease without invasive tests.
This trial is a national registry that collects information about people with lymphangioleiomyomatosis to better understand the condition and care over time. It may help by contributing real-world data from patients with sporadic disease or related tuberous sclerosis.
This study looks at the genes and physical traits of people with lymphangioleiomyomatosis (LAM), a rare lung disease that causes cysts. It aims to help better understand and treat LAM.
This trial studies whether sirolimus can be used safely and works over time for LAM, a rare lung disease. You may be able to join if you already use (or cannot use) certain lung-targeting medicines called mTOR inhibitors, and if you can do regular clinic visits and breathing tests.
Hear when a new Pulmonary Function trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.